InterVenn Company
InterVenn unlocks the glycoproteome using artificial intelligence for the development of transformational healthcare solutions in DX and Rx.
Total Funding:
$127.8M
Investor Type:
info@venn.bio
Technology:
Other
Last Funding Type:
Venture - Series Unknown
Investors Number:
7
Industry:
Medical BioTech
Headquarters:
South San Francisco, California, United States
Estimated Revenue:
$50M to $100M